One Platform. Endless Possibilities. SOI Annual Meeting of Stockholders

medical

JUNE 6, 2023 (PDT) / June 7, 2023 (AEST)

NASDAQ: RCEL ASX: AVH



No especial of the Board of AVITA Medical, Inc.

Representatives Present Today



Board of Directors	Officers
Lou PanaccioChair of the Board of Directors Chair of Today's MeetingJames CorbettJames CorbettChief Executive Officer and Executive DirectorJeremy Curnock-Cook Non-executive DirectorNon-executive DirectorProfessor Suzanne Crowe Non-executive DirectorJan Stern Reed Non-executive Director	Sean Ekins Interim Chief Financial Officer Donna Shiroma General Counsel

Robert McNamara

Cary Vance

Chris Cunningham U.S. Legal Adviser – Partner, K&L Gates LLP

Advisers

David Morris Australian Legal Adviser – Lander & Rogers

Breanna Taylor Australian Legal Adviser – Lander & Rogers

> Rod Somes Senior Relationship Manager – Computershare Australia


Mark Licciardo Australian Corporate Secretary – Acclime Australia



Introduction of Independent Registered Public Accounting Firm

Grant Thornton, LLP Represented by Cathy Hyodo

Experiencing Technical Difficulties?





Outside the U.S. please call: +1 (781) 575-2748

avia





Brief Company Overview



Appointment of Inspector of Election

Chairman to appoint Kerri Shenkin, Computershare US



Report By Secretary Of Mailing

Notice of Meeting



Presentation Of List Of Stockholders As Of Record Date

Available upon request



Report Of Quorum

Attendance at this meeting for a quorum

Polls for voting on all matters are open

Proposals – The Board of Directors recommend a vote FOR all of the nominees listed in Proposal 1, and a vote FOR Proposals 2-14, except where their personal interest in a Proposal causes them to abstain.



Election of Directors and Approval of Additional Matters

 \underline{J} o elect seven directors to serve a one-year term or until their \underline{F} espective successors have been duly elected and qualified.

- Lou Panaccio, Chairman of the Board of Directors
- James Corbett, Executive Director and Chief Executive Officer
- Jeremy Curnock Cook, Non-Executive Director
- **Professor Suzanne Crowe, Non-Executive Director**
- Jan Stern Reed, Non-Executive Director
- 6. Robert McNamara, Director Nominee
- 7. Cary Vance, Director Nominee

USe

Forpersonal



 \geq To ratify the appointment of Grant Thornton, LLP as the Company's Independent public accountants for the fiscal year ending December 31, 2023.

 \geq To approve the grant of restricted stock units to acquire shares of Common Stock (which may be represented by CDIs) equal in value So US\$87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock (which may be represented by \mathfrak{D} DIs) equal in value to US\$37,500 (at the time of the grant) to Mr. Lou Panaccio on the terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of AS Listing Rule **ქ0.11**.

To approve the grant of restricted stock units to acquire shares of equal in value Common Stock (which may be represented by CDIs) equal in value **To US\$87,500 (at the time of the grant) and the grant of options to Bacquire shares of Common Stock (which may be represented by** \mathcal{C} Dls) equal in value to US\$37,500 (at the time of the grant) to Professor Suzanne Crowe on the terms and conditions set out in The Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.

Proposal 5:

avita

Jo approve the grant of restricted stock units to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US\$87,500 (at the time of the grant) and the grant f options to acquire shares of common stock of the Company dwhich may be represented by CDIs) equal in value to US\$37,500 (at The time of the grant) to Mr. Jeremy Curnock Cook on the terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.

Proposal 6:

avita

Jo approve the grant of restricted stock units to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US\$87,500 (at the time of the grant) and the grant f options to acquire shares of common stock of the Company which may be represented by CDIs) equal in value to US\$37,500 (at The time of the grant) to Ms. Jan Stern Reed on the terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.

Proposal 7:

avita

Jo approve the grant of restricted stock units to acquire shares of Scommon stock of the Company (which may be represented by CDIs) equal in value to US\$147,000 (at the time of the grant) and the grant Sof options to acquire shares of common stock of the Company dwhich may be represented by CDIs) equal in value to US\$63,000 (at the time of the grant) to Mr. Robert McNamara on the terms and conditions set out in the Proxy Statement, pursuant to and for the Purposes of ASX Listing Rule 10.11 in recognition of Mr. McNamara , being appointed as a new director of the Company during 2023.

Proposal 8:

avita

Jo approve the grant of restricted stock units to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US\$87,500 (at the time of the grant) and the grant f options to acquire shares of common stock of the Company which may be represented by CDIs) equal in value to US\$37,500 (at the time of the grant) to Mr. Robert McNamara on the terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.

Proposal 9:

avita

Jo approve the grant of restricted stock units to acquire shares of **S**common stock of the Company (which may be represented by CDIs) equal in value to US\$147,000 (at the time of the grant) and the grant Sof options to acquire shares of common stock of the Company dwhich may be represented by CDIs) equal in value to US\$63,000 (at time of the grant) to Mr. Cary Vance on the terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11 in recognition of Mr. Vance being appointed as a new director of the Company during 2023.

Proposal 10:

avita

Jo approve the grant of restricted stock units to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US\$87,500 (at the time of the grant) and the grant **Sof options to acquire shares of common stock of the Company** dwhich may be represented by CDIs) equal in value to US\$37,500 (at The time of the grant) to Mr. Cary Vance on the terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.

Proposal 11:

avia

Jo approve the grant of options to acquire 100,000 shares of Sommon stock of the Company (which may be represented by CDIs) to Mr. James Corbett, Chief Executive Officer of the Company, on She terms and conditions set out in the Proxy Statement, pursuant To and for the purposes of ASX Listing Rule 10.11.

Proposal 12:

avita

Jo approve (a) an amendment to the 2020 Omnibus Incentive Plan **⊈**the "Plan"), the terms of which are summarized in the Proxy Statement (the "Plan Amendment); and (b) for purposes of ASX Listing Rule 7.2 Exception 13(b) and for all other purposes, the ressue of equity securities in the Company under and subject to the derms of the Plan for three years commencing on the date that this proposal is approved by the Company's stockholders as an exception to ASX Listing Rule 7.1.

Proposal 13:

avita

Jo approve (a) the adoption of the Company's Employee Stock Purchase Plan (the "ESPP"), the terms of which are **Summarized in the Proxy Statement; and (b) for the** purposes of ASX Listing Rule 7.2 Exception 13(b) and for all other purposes, the issue of equity securities in the Company under and subject to the terms of the ESSP within three years from the date that this proposal is **Approved by the Company's stockholders as an exception** ASX Listing Rule 7.1.

Proposal 14:

avita

Advisory vote to approve the compensation of the Company'samed executive officers.



Closing of Polls

The polls are about to close so if you have not yet voted, please do so.


We will announce the results of the voting as soon as possible following the close of this meeting via announcements to be filed with the U.S. Securities and Exchange Commission and the Australian Securities Exchange.



Adjournment of Meeting and General Question and Answer Period

The formal business of the meeting is now closed.

We invite you to now ask any questions you may have as it relates to the content of today's meeting. Please follow the instructions provided on the Virtual Meeting Screen.



Conclusion of Annual Meeting of Stockholders avita



Thank you!

One Platform. **Aultiple Indications.**

medical

Accelerating Our Growth Profile **2**023 Corporate Update June 6, 2023

NASDAQ: RCEL

Medical Redical

Forward-Looking Statements & Legal Disclaimers



Certain statements in this presentation and the accompanying oral commentary are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, echnology platform, development strategy, prospective products, pipeline and milestones, regulatory objectives, expected payments from and outcomes of collaborations, and likelihood of success, are forward-looking statements. Such statements are predictions only and involve known and unknown risks, uncertainties and other important foctors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, the costs, timing and results of clinical trials and other development divivities; the uncertainties inherent in the initiation and enrollment of clinical trials; the uncertainties associated with the COVID-19 pandemic; the unpredictability of the phairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting risks and litigation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are forementioned risks and uncertainties is available in our public filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on molerake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise, except as required by law. Additional molerake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise, except as required by law. Additional formatio

WITA Medical's products are Rx only. Please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions and adverse events.

The United States, RECELL[®] is approved for use in patients suffering acute thermal burns. Use of RECELL in other patient populations is either prohibited by United States w or may be made available pursuant to a relevant investigational device exemption granted by the FDA (and likewise limited by United States law to investigational use United States). USe

or personal



Regenerative medicine company transforming the standard of care for skin restoration with its innovative cellular technology platform, the **RECELL® System**

RECELL System includes autologous cell harvesting device that prepares, produces, and delivers regenerative cellular suspension, **Spray-On Skin™ Cells**, within 30 minutes at the point of care.

Spray-On Skin Cells contain cells necessary to regenerate patient's outer layer of natural, healthy skin as well as cells that modulate and **catalyze healing process**

Current U.S. indication: acute thermal burns

Pending U.S. indications: PMA supplement for soft tissue repair, PMA application for vitiligo


Core advantages:

- Utilizes small skin sample from patient; significantly less skin relative to conventional skin graft treatment
- Suspension created at patient's bedside within 30 minutes, further supports healing at the cellular level
- Multi-cell regenerative therapy in single point-of-care procedure, reducing hospital length of stay


In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

What is RECELL?

avita








2023 Highlights & Milestones

- Commercial Revenue Growth:
 - First guarter 2023: 40% same guarter prior year
- only Field Sales Organization:
 - Initiated recruiting and hiring process; grew from 30 to 69 towards goal of 70
 - Onboarding and training underway and ahead of schedule.
- For personal Soft Tissue Repair:
 - Expect FDA approval in June 2023 followed by commercial launch on July 1, 2023
 - FDA Breakthrough Device Designation
 - Vitiligo:

USe

- Expect FDA approval in June 2023; pursing reimbursement for the use of RECELL in office, which is expected in 2025
- FDA Breakthrough Device Designation
- **RECELL GO Device:**
 - Anticipate FDA submission by June 30, 2023
 - Maintains FDA Breakthrough Device Designation

Strong U.S. RECELL **Commercial Growth**



Soft Tissue Repair Opportunity

avita

Female, pregnant 28-year-old who suffered from a de-gloving injury



POST DEBRIDEMENT OF INJURY



6 MONTH POST-RECELL TREATMENT

Poster: Use of regenerative suspension in the treatment of a complex de-gloving injury. Ian M Smith.

Submitted PMA Supplement in December 2022

► Expect FDA approval in June 2023

Following approval, launching July 2023
 Significant synergies between Burns and


Significant synergies between Burns and Soft Tissue Repair;
 driving growth over the next 3+ years

Soft Tissue Repair expands business to encompass all acute wounds

In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. In the United States, RECELL is not approved for use in pediatrics. Use of RECELL in this case was performed internationally where the indication is approved.



Meaningfully Broadens Acute Wounds Business by Soft Tissue Repair Indication



Eligible procedures at targeted call points: 145,000+

- Soft Tissue Repair in-patient reimbursement: same DRG code as Burns; *effective immediately* upon FDA approval
- Soft Tissue Repair out-patient transitional pass-through code (TPTC): same code as Burns; *effective immediately* upon FDA approval
 - Of ~150 burn centers, 50% are also either level 1 or level 2 trauma centers; *immediate access* to expanded label upon approval
 - Approximately 30% of Burns are treated outside of burn centers within level 1 or level 2 trauma centers; thus, expansion into these trauma centers allows sales force to capture remaining portion of burn market
 - In April 2023, sales force started the Value Analysis Committee discussions in level 1 and level 2 trauma centers
 - Expanded sales force from 30 to 69, towards our goal of 70 ahead of July 1 launch of Soft Tissue Repair
 - AVITA Medical growth over the next three to five years expected to be fueled by Soft Tissue Repair and Burns

Synergies enhance commercial launch of Soft Tissue Repair expected in July 2023

Vitiligo Opportunity

avita

Submitted PMA application in December 2022 with study results:

- Primary endpoint: proportion of study sites achieving ≥80% repigmentation for RECELL-treated sites vs Control at Week 24
- Super-superiority was established for the primary endpoint (p<0.025)

Expect FDA approval in June 2023

Proposed RECELL indication represents first-in-class repigmentation transplantation of melanocytes

Plans for 2023 – 2024:

6000

Ω


- Conduct post-approval approximate 100 patient study to demonstrate the cure and mental health benefits of vitiligo treatment
- Vitiligo market five times the size of combined Burns and Soft Tissue Repair
- Vitiligo opens significant market application of RECELL
- Site of service reimbursement for RECELL in office expected 2025

Advances in Vitiligo: An Update on Medical and Surgical Treatments. A. Dillon, et al. J Clin Aesth Derm. 2017. Willingness-to-Pay and Quality of Life in Patients with Vitiligo. Radtke, et al. BJD. 2009.

In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

First-in-class re-pigmentation transplantation of melanocytes

Patient from a prior study at six-months RECELL-treated area was 100% re-pigmented



Komen L, Vrijman C, Tjin EP, Krebbers G, de Rie MA, Luiten RM, van der Veen JW, Wolkerstorfer A. Autologous cell suspension transplantation using a cell extraction device in segmental vitiligo and piebaldism patients: a randomized controlled pilot study. Journal of the American Academy of Dermatology. 2015 Jul;73(1):170-2.

RECELL treatment against "control" unmatched at six months

*NB-UVB protocol per Vitiligo Working Group recommendations JAAD 2017. In the United States, RECELL is not approved for treatment of vitiligo.

2023: A Year of Inflection





Expecting FDA approvals for two indications: Soft Tissue Repair and Vitiligo

Soft Tissue Repair: anticipated launch in July 2023; ~5x market expansion will fuel revenue growth ersonaluse

Vitiligo: ~5x patient population of Burns and Soft Tissue Repair, combined; pursuing reimbursement for RECELL in physician setting

RECELL GO: anticipating FDA submission by June 30, 2023





Soft Tissue Repair and Vitiligo greatly expand U.S. market opportunity

•	medical
avi	I A

\geq		Unaudited Three-Months Ended March 31		
UC	(USD in \$000s)	2022	2023	
NSG (Commercial Sales	7,446	10,458	
	BARDA Sales	93	92	
	Total Revenue	7,539	10,550	
na	Gross Profit	5,761	8,883	
LSO	BARDA Income	734	627	
or pe	Cash, Cash Equivalents & Marketable Securities	95,054	77,640	

Analysts			NASDAQ ticker	ASX ticker
 Josh Jennings, Cowen (U.S.) Matt O'Brien, Piper (U.S.) Ryan Zimmerman, BTIG (U.S.) 	 Brooks O'Neil, Lake Street (U.S.) John Hester, Bell Potter (AUS) Lyanne Harrison, BofA Global Research (AUS) 	 Scott Power, Morgans (AUS) Chris Kallos, MST (AUS) Shane Storey, Wilsons (AUS) 	symbol: RCEL	symbol: AVH

Financial Guidance

Commercial revenue, excluding BARDA revenue:

- Q2 2023: \$10.7 \$11.7 million
- JSG 2023: \$49 – \$51 million

Future Milestones

- persona Expected approval of PMA supplement for soft tissue repair indication in June 2023 followed by commercial launch on July 1, 2023
 - Expected approval of PMA application for vitiligo indication in June 2023
 - Anticipate FDA submission of RECELL GO by June 30, 2023

Burns

- Core Burn centers will continue to penetrate, adopt and grow
- Burns utilization will expand, accessing ~30% of market not currently called on by AVITA Medical Burns sales team
- Strong healthcare economics drive in-patient adoption; TPTC broadens coverage

) Soft Tissue Repair

- Represents ~5x expansion of Burn center market opportunity in level 1 and level 2 trauma centers
- Reimbursement starts DAY 1 using same codes and reimbursement as Burns

T Vitiligo

- Represents ~5x patient population of Burns and Soft Tissue Repair, combined; opens significant market application
- Pursuing reimbursement for RECELL within the physician setting, expected 2025

RECELL GO

- Evolutionary design of existing RECELL technology designed to automate cell disaggregation process; eases training burden
- Critical component of platform that will greatly accelerate our growth

Outlook over next 3 to 5 years

- AVITA Medical growth driven by U.S. Burns and Soft Tissue Repair
- Vitiligo expected market adoption in 2025
- International expansion plans communicated by end-of-year 2023

Revolutionary treatment using a patient's own skin for life-changing outcomes

avita

In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

Zed, treated with the RECELL[®] System

• INDICATIONS FOR USE: The RECELL® Autologous Cell Harvesting Device is indicated for the treatment of acute thermal burn wounds. The RECELL device is used by an appropriately-licensed healthcare professional at the patient's point of care to prepare autologous RES® Regenerative Epidermal Suspension for direct application to acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients.

CONTRAINDICATIONS: RECELL is contraindicated for: the treatment of wounds clinically diagnosed as infected or with necrotic tissue, the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate (Hartmann's) solution, patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions.

WARNINGS: Autologous use only. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL is provided sterile and is intended for single-use. Do not use if packaging is damaged or expired. Choose a donor site with no evidence of cellulitis or infection and process skin immediately. A skin sample should require between 15 and 30 minutes contact with Enzyme. Contact in excess of 60 minutes is not recommended. RECELL Enzyme is animal derived and freedom from infectious agents cannot be guaranteed.

PRECAUTIONS: RECELL is not intended for use without meshed autograft for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL without meshed autograft for treatment of partial-thickness burn wounds: on the hands and articulating joints, >320 cm2, in patients with wounds totaling >20% total body surface area (TBSA). The safety and effectiveness of RECELL with autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulating for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL with autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulated joints, and in patients younger than 28 days of age (neonates).

SPECIAL PATIENT POPULATIONS: The safety and effectiveness of RECELL have not been established for treatment of acute thermal partial-thickness burn wounds in pediatric patients younger than 18 years of age.